It has been reported that Japanese small-cap biotech company Chiome Bioscience, Inc. and FRONTEO, which operates in the AI drug discovery field, have formed a partnership. The specific terms of the partnership and its future development are expected to become clear in subsequent reports.
Based on reports that Chiome Bioscience, Inc. and FRONTEO have formed a partnership, it has been reported that the two companies intend to advance cooperation in the AI drug discovery field.
The article explains that the companies are expected to seek greater efficiency in the drug discovery process through the use of AI technology in collaboration with FRONTEO, and says attention is focused on the announcement of specific initiatives and results going forward.